[ Price : $8.95]
FDA lifts a partial clinical hold on the Curis Phase 1/2 trial of emavusertib in the TakeAim Leukemia study.[ Price : $8.95]
Three Hogan Lovells attorneys say a recently finalized FDA guidance on DTC drug promotion may signal an increase in promotion enfo...[ Price : $8.95]
DA says a cybersecurity vulnerability in several Illumina DNA sequencing devices is Class 2.[ Price : $8.95]
Ipsen says it plans to file a regulatory application with FDA for its elafibranor to treat adults with primary biliary cholangitis...[ Price : $8.95]
FDA converts Eisais Alzheimers drug Leqembi from accelerated to traditional approval based on the results of a confirmatory trial ...[ Price : $8.95]
Reed Smith attorneys analyze an FDA draft guidance on the Section 503B wholesaling prohibition.[ Price : $8.95]
FDA issues a complete response letter for a Regeneron BLA for aflibercept 8 mg, citing its review of a third-party filler inspecti...[ Price : $8.95]
Four Sidley Austin attorneys say FDA is planning to issue a notice of proposed rulemaking to assert its authority to regulate labo...